The companies kept the terms of the agreement confidential.
Marina Biotech president and chief executive officer Michael French said, "We view this license as yet another important validation of this platform and we look forward to a strong and growing relationship with Monsanto."
Marina Biotech is focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking.